New CAR T-Cell therapy targets Hard-to-Treat blood cancers
NCT ID NCT07503353
First seen Apr 04, 2026 · Last updated May 01, 2026 · Updated 2 times
Summary
This study tests a new treatment called SHB-02-CD19 for people with certain blood cancers (B-cell malignancies) that have come back or not responded to standard therapy. The treatment uses the patient's own immune cells, which are modified in a lab to recognize and attack cancer cells. The study aims to see if this therapy is safe and effective in up to 50 children and adults.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBKASTIC LEUKEMIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sheba Medical Center
Ramat Gan, Israel
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.